GB2481018B - Injectable flowable composition comprising buprenorphine - Google Patents

Injectable flowable composition comprising buprenorphine

Info

Publication number
GB2481018B
GB2481018B GB1009549.5A GB201009549A GB2481018B GB 2481018 B GB2481018 B GB 2481018B GB 201009549 A GB201009549 A GB 201009549A GB 2481018 B GB2481018 B GB 2481018B
Authority
GB
United Kingdom
Prior art keywords
buprenorphine
flowable composition
injectable flowable
injectable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1009549.5A
Other languages
English (en)
Other versions
GB201009549D0 (en
GB2481018A (en
Inventor
Richard Norton
Andrew Watkins
Mingxing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Original Assignee
RB Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2481018(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RB Pharmaceuticals Ltd filed Critical RB Pharmaceuticals Ltd
Priority to GB1413064.5A priority Critical patent/GB2513267B/en
Priority to GB1009549.5A priority patent/GB2481018B/en
Publication of GB201009549D0 publication Critical patent/GB201009549D0/en
Priority to PT117280370T priority patent/PT2579874T/pt
Priority to EP17205986.7A priority patent/EP3360538B1/en
Priority to ES11728037.0T priority patent/ES2656938T3/es
Priority to LTEP11728037.0T priority patent/LT2579874T/lt
Priority to MYPI2012005274A priority patent/MY171625A/en
Priority to EP23150636.1A priority patent/EP4218720A1/en
Priority to RU2012157244A priority patent/RU2607498C2/ru
Priority to BR112012031290A priority patent/BR112012031290A2/pt
Priority to KR1020127032282A priority patent/KR101865689B1/ko
Priority to FIEP17205986.7T priority patent/FI3360538T3/fi
Priority to RS20180068A priority patent/RS56820B1/sr
Priority to DK11728037.0T priority patent/DK2579874T3/da
Priority to PCT/GB2011/051057 priority patent/WO2011154724A2/en
Priority to SI201131401T priority patent/SI2579874T1/en
Priority to HUE11728037A priority patent/HUE038275T2/hu
Priority to MX2012014335A priority patent/MX339209B/es
Priority to NO11728037A priority patent/NO2579874T3/no
Priority to NZ604026A priority patent/NZ604026A/en
Priority to DK17205986.7T priority patent/DK3360538T3/da
Priority to AU2011263478A priority patent/AU2011263478B2/en
Priority to ES17205986T priority patent/ES2939612T3/es
Priority to CA2801676A priority patent/CA2801676C/en
Priority to PL11728037T priority patent/PL2579874T3/pl
Priority to SG2012089652A priority patent/SG186200A1/en
Priority to SM20180038T priority patent/SMT201800038T1/it
Priority to CN201180039223.3A priority patent/CN103079544B/zh
Priority to JP2013513755A priority patent/JP5986072B2/ja
Priority to EP11728037.0A priority patent/EP2579874B1/en
Priority to HRP20180118TT priority patent/HRP20180118T1/hr
Priority to US13/703,013 priority patent/US8921387B2/en
Publication of GB2481018A publication Critical patent/GB2481018A/en
Priority to ZA2012/09233A priority patent/ZA201209233B/en
Priority to IL223488A priority patent/IL223488A/en
Priority to CL2012003462A priority patent/CL2012003462A1/es
Priority to CO13001795A priority patent/CO6670529A2/es
Priority to US13/836,134 priority patent/US8975270B2/en
Priority to US14/610,818 priority patent/US9272044B2/en
Application granted granted Critical
Publication of GB2481018B publication Critical patent/GB2481018B/en
Priority to US14/995,053 priority patent/US9498432B2/en
Priority to JP2016110259A priority patent/JP6251774B2/ja
Priority to US15/334,000 priority patent/US9782402B2/en
Priority to US15/623,191 priority patent/US9827241B2/en
Priority to IL254417A priority patent/IL254417A0/en
Priority to US15/820,048 priority patent/US10558394B2/en
Priority to US15/857,507 priority patent/US10198218B2/en
Priority to CY181100098T priority patent/CY1120761T1/el
Priority to US16/693,726 priority patent/US10592168B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB1009549.5A 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine Active GB2481018B (en)

Priority Applications (47)

Application Number Priority Date Filing Date Title
GB1413064.5A GB2513267B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
CA2801676A CA2801676C (en) 2010-06-08 2011-06-06 Compositions
SM20180038T SMT201800038T1 (it) 2010-06-08 2011-06-06 Composizione fluida iniettabile comprendente buprenorfina
ES11728037.0T ES2656938T3 (es) 2010-06-08 2011-06-06 Composición que fluye inyectable que comprende buprenorfina
LTEP11728037.0T LT2579874T (lt) 2010-06-08 2011-06-06 Injekuojama skysta kompozicija, apimanti buprenorfiną
MYPI2012005274A MY171625A (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
EP23150636.1A EP4218720A1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
RU2012157244A RU2607498C2 (ru) 2010-06-08 2011-06-06 Жидкотекучие композиции для инъекций, включающие бупренорфин
BR112012031290A BR112012031290A2 (pt) 2010-06-08 2011-06-06 composição fluidificável injetável compreendendo buprenorfina
KR1020127032282A KR101865689B1 (ko) 2010-06-08 2011-06-06 부프레노르핀을 포함하는 주입가능한 유동성 조성물
FIEP17205986.7T FI3360538T3 (fi) 2010-06-08 2011-06-06 Injektoitava, juokseva koostumus käsittäen buprenorfiinia
RS20180068A RS56820B1 (sr) 2010-06-08 2011-06-06 Injektabilna tečna kompozicija koja sadrži buprenorfin
DK11728037.0T DK2579874T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions
SI201131401T SI2579874T1 (en) 2010-06-08 2011-06-06 INJECTION LIQUID COMPONENTS, EXPLOSIVE BUPRENORPHIN
HUE11728037A HUE038275T2 (hu) 2010-06-08 2011-06-06 Buprenorfin tartalmú injektálható, folyékony készítmény
MX2012014335A MX339209B (es) 2010-06-08 2011-06-06 Composiciones.
NO11728037A NO2579874T3 (enExample) 2010-06-08 2011-06-06
NZ604026A NZ604026A (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
DK17205986.7T DK3360538T3 (da) 2010-06-08 2011-06-06 Injicerbar, flydende sammensætning omfattende buprenorphin
EP17205986.7A EP3360538B1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
ES17205986T ES2939612T3 (es) 2010-06-08 2011-06-06 Composición fluyente inyectable que comprende buprenorfina
PT117280370T PT2579874T (pt) 2010-06-08 2011-06-06 Composição fluidificável injetável que compreende buprenorfina
PL11728037T PL2579874T3 (pl) 2010-06-08 2011-06-06 Płynna kompozycja do wstrzykiwania zawierająca buprenorfinę
SG2012089652A SG186200A1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
AU2011263478A AU2011263478B2 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
CN201180039223.3A CN103079544B (zh) 2010-06-08 2011-06-06 包含丁丙诺啡的可注射的可流动组合物
JP2013513755A JP5986072B2 (ja) 2010-06-08 2011-06-06 組成物
EP11728037.0A EP2579874B1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
HRP20180118TT HRP20180118T1 (hr) 2010-06-08 2011-06-06 Injekcijski tekući pripravak koji sadrži buprenorfin
US13/703,013 US8921387B2 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine
ZA2012/09233A ZA201209233B (en) 2010-06-08 2012-12-06 Injectable flowable composition cimprising buprenorphine
IL223488A IL223488A (en) 2010-06-08 2012-12-06 Injectable flow bar preparation containing buprenorphine
CL2012003462A CL2012003462A1 (es) 2010-06-08 2012-12-07 Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.
CO13001795A CO6670529A2 (es) 2010-06-08 2013-01-04 Sistema de suministro de buprenorfina de liberación sostenida
US13/836,134 US8975270B2 (en) 2010-06-08 2013-03-15 Injectable flowable composition comprising buprenorphine
US14/610,818 US9272044B2 (en) 2010-06-08 2015-01-30 Injectable flowable composition buprenorphine
US14/995,053 US9498432B2 (en) 2010-06-08 2016-01-13 Injectable flowable composition comprising buprenorphine
JP2016110259A JP6251774B2 (ja) 2010-06-08 2016-06-01 組成物
US15/334,000 US9782402B2 (en) 2010-06-08 2016-10-25 Injectable composition comprising buprenorphine
US15/623,191 US9827241B2 (en) 2010-06-08 2017-06-14 Injectable flowable composition comprising buprenorphine
IL254417A IL254417A0 (en) 2010-06-08 2017-09-11 A flowable, injectable preparation containing buprenorphine
US15/820,048 US10558394B2 (en) 2010-06-08 2017-11-21 Injectable flowable composition comprising buprenorphine
US15/857,507 US10198218B2 (en) 2010-06-08 2017-12-28 Injectable flowable composition comprising buprenorphine
CY181100098T CY1120761T1 (el) 2010-06-08 2018-01-24 Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινη
US16/693,726 US10592168B1 (en) 2010-06-08 2019-11-25 Injectable flowable composition comprising buprenorphine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Publications (3)

Publication Number Publication Date
GB201009549D0 GB201009549D0 (en) 2010-07-21
GB2481018A GB2481018A (en) 2011-12-14
GB2481018B true GB2481018B (en) 2015-03-18

Family

ID=42471306

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1009549.5A Active GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
GB1413064.5A Active GB2513267B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1413064.5A Active GB2513267B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Country Status (32)

Country Link
US (1) US8921387B2 (enExample)
EP (3) EP3360538B1 (enExample)
JP (2) JP5986072B2 (enExample)
KR (1) KR101865689B1 (enExample)
CN (1) CN103079544B (enExample)
AU (1) AU2011263478B2 (enExample)
BR (1) BR112012031290A2 (enExample)
CA (1) CA2801676C (enExample)
CL (1) CL2012003462A1 (enExample)
CO (1) CO6670529A2 (enExample)
CY (1) CY1120761T1 (enExample)
DK (2) DK3360538T3 (enExample)
ES (2) ES2656938T3 (enExample)
FI (1) FI3360538T3 (enExample)
GB (2) GB2481018B (enExample)
HR (1) HRP20180118T1 (enExample)
HU (1) HUE038275T2 (enExample)
IL (2) IL223488A (enExample)
LT (1) LT2579874T (enExample)
MX (1) MX339209B (enExample)
MY (1) MY171625A (enExample)
NO (1) NO2579874T3 (enExample)
NZ (1) NZ604026A (enExample)
PL (1) PL2579874T3 (enExample)
PT (1) PT2579874T (enExample)
RS (1) RS56820B1 (enExample)
RU (1) RU2607498C2 (enExample)
SG (1) SG186200A1 (enExample)
SI (1) SI2579874T1 (enExample)
SM (1) SMT201800038T1 (enExample)
WO (1) WO2011154724A2 (enExample)
ZA (1) ZA201209233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
ES2837803T3 (es) * 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9592227B2 (en) * 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
JP6723162B2 (ja) * 2014-04-21 2020-07-15 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ポリオルトエステルおよび有機酸添加剤の組成物
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CN106535886A (zh) 2014-04-21 2017-03-22 赫伦治疗有限公司 长效聚合物输送系统
AU2015253417B2 (en) 2014-04-28 2020-02-20 Dimerx, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
US20160128997A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
PL3512518T3 (pl) * 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
NZ760033A (en) 2017-06-16 2023-02-24 Indivior Uk Ltd Methods to treat opioid use disorder
WO2019144079A1 (en) 2018-01-22 2019-07-25 Yuhua Li Pharmaceutical composition for sustained release delivery of buprenorphine
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
WO2020077235A1 (en) 2018-10-11 2020-04-16 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US7368126B2 (en) * 2002-11-06 2008-05-06 Guohua Chen Controlled release depot formulations
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
EP1824460B1 (en) * 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
EP3202814B1 (en) 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040033250A1 (en) * 2002-05-31 2004-02-19 Patel Rajesh A. Implantable polymeric device for sustained release of buprenorphine
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAPS PharmSciTech, 2007, Graves, R.A. et al., In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note, pp. E1 to E4. *

Also Published As

Publication number Publication date
GB201009549D0 (en) 2010-07-21
KR20130135026A (ko) 2013-12-10
GB2513267B (en) 2015-03-18
RU2012157244A (ru) 2014-07-20
CO6670529A2 (es) 2013-05-15
BR112012031290A2 (pt) 2016-11-01
SI2579874T1 (en) 2018-03-30
MX2012014335A (es) 2013-03-05
SMT201800038T1 (it) 2018-03-08
GB2513267A (en) 2014-10-22
CA2801676A1 (en) 2011-12-15
AU2011263478B2 (en) 2015-01-22
WO2011154724A9 (en) 2012-08-16
IL254417A0 (en) 2017-11-30
EP3360538A1 (en) 2018-08-15
CY1120761T1 (el) 2019-12-11
GB2481018A (en) 2011-12-14
ZA201209233B (en) 2014-04-30
CL2012003462A1 (es) 2013-04-01
IL223488A (en) 2017-10-31
LT2579874T (lt) 2018-02-12
WO2011154724A2 (en) 2011-12-15
JP2016155865A (ja) 2016-09-01
JP6251774B2 (ja) 2017-12-20
EP2579874B1 (en) 2018-01-10
NZ604026A (en) 2015-01-30
PL2579874T3 (pl) 2018-05-30
MX339209B (es) 2016-04-15
US8921387B2 (en) 2014-12-30
PT2579874T (pt) 2018-01-29
EP3360538B1 (en) 2023-02-15
HUE038275T2 (hu) 2018-10-29
AU2011263478A1 (en) 2013-01-10
ES2939612T3 (es) 2023-04-25
WO2011154724A3 (en) 2012-07-12
DK2579874T3 (da) 2018-01-29
JP2013533230A (ja) 2013-08-22
US20130210853A1 (en) 2013-08-15
HRP20180118T1 (hr) 2018-03-09
EP4218720A1 (en) 2023-08-02
RS56820B1 (sr) 2018-04-30
RU2607498C2 (ru) 2017-01-10
NO2579874T3 (enExample) 2018-06-09
CA2801676C (en) 2018-08-07
EP2579874A2 (en) 2013-04-17
ES2656938T3 (es) 2018-03-01
GB201413064D0 (en) 2014-09-03
MY171625A (en) 2019-10-21
DK3360538T3 (da) 2023-03-06
JP5986072B2 (ja) 2016-09-06
CN103079544A (zh) 2013-05-01
CN103079544B (zh) 2017-06-09
KR101865689B1 (ko) 2018-06-08
FI3360538T3 (fi) 2023-03-22
SG186200A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
IL254417A0 (en) A flowable, injectable preparation containing buprenorphine
GB201002983D0 (en) Nutritinal composition
GB201006699D0 (en) Composition
GB201021186D0 (en) Composition
SI2579875T1 (sl) Sestavki obsegajoči buprenorfin
ZA201207055B (en) Composite additive materials
EP2570141A4 (en) DERIVATIVE FILLING COMPOSITION
GB201006178D0 (en) Composition
GB201021269D0 (en) Composition
GB201017048D0 (en) Composition
GB201016970D0 (en) Composition
IL206739A0 (en) Injectable pharmaceutical composition
ZA201303199B (en) Herbicicdal composition
GB201006214D0 (en) Composition
SI2625258T1 (sl) Sestavek za čiščenje polimerov
GB201019988D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201014967D0 (en) Composition
GB201010657D0 (en) Composition
GB201018130D0 (en) Composition
GB201006175D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
GB201003347D0 (en) Tppical composition

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20120927 AND 20121003

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20150129 AND 20150204